Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S ( (DE:2TZ) ) just unveiled an announcement.
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited has issued a monthly update on the bankruptcy liquidation of its 55%-owned subsidiary, Tianjin Shin Poong Pharmaceutical Co., Ltd., incorporated in China. The group operates in the pharmaceutical industry, producing and distributing medicines and related healthcare products through its various subsidiaries.
The board reported that there have been no material developments in the subsidiary’s bankruptcy proceedings that would significantly affect the company’s financial position since the previous monthly update. The company will continue to monitor the case, maintain communication with the court and the administrator, and provide ongoing monthly updates in line with listing rules, while urging shareholders and potential investors to exercise caution when trading its shares.
More about Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited, is a China-incorporated pharmaceutical group engaged in the manufacture and sale of pharmaceutical products through its subsidiaries, serving the healthcare and medicine markets in the People’s Republic of China and abroad.
Learn more about 2TZ stock on TipRanks’ Stock Analysis page.